Kiniksa Pharmaceuticals saw the highest growth of 1.99% in patent filings in April and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Kiniksa Pharmaceuticals‘s patent filings and grants. Buy the databook here.
Kiniksa Pharmaceuticals has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 50% of filings. The Australia(AU), European Patent Office(EPO), United States(US), and Poland(PL) patent Office are among the top ten patent offices where Kiniksa Pharmaceuticals is filings its patents. Among the top granted patent authorities, Kiniksa Pharmaceuticals has 50% of its grants in United States(US) and 50% in Poland(PL).
Regeneron Pharmaceuticals and Roche could be the strongest competitors for Kiniksa Pharmaceuticals
Patents related to rare diseases and addiction lead Kiniksa Pharmaceuticals's portfolio
Kiniksa Pharmaceuticals has the highest number of patents in rare diseases followed by, addiction and Covid-19. For rare diseases, nearly 50% of patents were filed and 50% of patents were granted in Q2 2024.
Inflammation related patents lead Kiniksa Pharmaceuticals portfolio followed by pericarditis, and coronavirus disease 2019 (covid-19)
Kiniksa Pharmaceuticals has highest number of patents in inflammation followed by pericarditis, coronavirus disease 2019 (covid-19), cough, and pneumonia. For inflammation, nearly 5% of patents were filed and 25% of patents were granted in Q2 2024.
For comprehensive analysis of Kiniksa Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.